AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance

AbbVie (NYSE: ABBV) reported Q1 EPS of $2.14, $0.08 better than the analyst estimate of $2.06. Revenue for the quarter came in at $7.83 billion versus the consensus estimate of $7.76 billion.

GUIDANCE:

AbbVie sees FY2019 EPS of $8.73-$8.83, versus the consensus of $8.69.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• EPR Properties (EPR) Reiterated at Market Outperform by Citizens on Strong Momentum